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ABSTRACT
Gene-editing nucleases enable targeted modification
of DNA sequences in living cells, thereby facilitating
efficient knockout and precise editing of endogenous
loci. Engineered nucleases also have the potential to
introduce mutations at off-target sites of action.
Such unintended alterations can confound interpret-
ation of experiments and can have implications for
development of therapeutic applications. Recently,
two improved methods for identifying the off-target
effects of zinc finger nucleases (ZFNs) were
described–one using an in vitro cleavage site selec-
tion method and the other exploiting the insertion of
integration-defective lentiviruses into nuclease-
induced double-stranded DNA breaks. However, ap-
plication of these twomethods to a ZFN pair targeted
to the human CCR5 gene led to identification of
largely non-overlapping off-target sites, raising the
possibility that additional off-target sites might
exist. Here, we show that in silico abstraction of
ZFN cleavage profiles obtained from in vitro
cleavage site selections can greatly enhance the
ability to identify potential off-target sites in human
cells. Our improved method should enable more
comprehensive profiling of ZFN specificities.
INTRODUCTION
Gene-editing nucleases, such as zinc ﬁnger nucleases
(ZFNs), transcription activator-like effector nucleases
(TALENs) and clustered regularly interspaced short pal-
indromic repeats (CRISPR)/CRISPR-associated (Cas)
nucleases, can be used to create targeted sequence alter-
ations with high efﬁciencies in numerous cell types and
organisms (1–7). Repair of nuclease-induced double-
stranded breaks can be exploited to introduce either
insertion/deletion (indel) mutations via non-homologous
end-joining (NHEJ) or speciﬁc sequence alterations from
a donor template via homology-directed repair (1,2).
Comprehensive delineation of unintended off-target
mutations is important for customized nucleases in
many biological applications and will be essential for de-
veloping therapeutic strategies based on these proteins.
Two different methods have recently been described for
characterizing the genome-wide speciﬁcities of ZFNs (8,9),
but neither study comprehensively identiﬁed the full-
spectrum of possible off-target mutations. One method,
previously developed by Liu and colleagues, used an
in vitro cleavage site selection assay to identify sequences
from a large partially degenerate library (based on the
intended target DNA site) that can be cleaved by ZFNs.
In vitro selections with a CCR5-targeted ZFN pair
identiﬁed 36 potential off-target cleavage sites that occur
in the sequence of the human genome; analysis of these
sites in human cells in which CCR5-targeted ZFNs had
been expressed revealed nine bona ﬁde off-target sites (8).
Another approach, described by von Kalle and colleagues,
exploited the incorporation of integrase-deﬁcient lenti-
virus (IDLV) DNAs into nuclease-induced double-
stranded breaks to map ZFN cleavage sites in human
cells (9). Application of this approach to the same
CCR5-targeted ZFNs characterized with the in vitro selec-
tion approach identiﬁed four off-target genomic sites.
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However, the substantial lack of overlap between off-
target sites identiﬁed in these two studies (only one site
was common to both sets) strongly suggested that neither
identiﬁed all possible off-target sites. In addition, these
results also suggested that a broader range of potential
off-target sites might exist beyond the sets identiﬁed by
these two methods.
Here, we show that in silico abstraction of ZFN
cleavage proﬁles generated by the selection method of
Liu and colleagues provides an improved approach to
screen the human genome for potential ZFN off-target
sites. This enhanced strategy identiﬁes both previously
described as well as dozens of additional off-target sites
for a ZFN pair targeted to CCR5 gene. We also show that
this improved method works effectively for another ZFN
pair targeted to the VEGFA gene. Our results demonstrate
that the potential landscape of off-target mutagenesis
effects for ZFNs may be broader than delineated in
previous studies.
MATERIALS AND METHODS
Plasmids
The plasmids encoding ZFNs targeted to sites in the
human CCR5 (10) and VEGFA (11) genes were modiﬁed
to include heterodimeric EL/KK FokI mutations (12) and
were constructed as described in Pattanayak et al. (8)
(Supplementary Figure S1).
Processing of in vitro selection data
Sequence reads from the in vitro cleavage assay reported
by Pattanayak were used to generate nucleotide windows
comprising the core 9 bp (VEGFA) and 12 bp (CCR5) zinc
ﬁnger recognition sites as well as the adjacent nucleotides
for each ZFN half-site. Sequences shown to cleave efﬁ-
ciently in vitro were considered active. The preselection
library sequences minus those seen in the active set were
considered not efﬁciently cleaved and labeled as the
inactive class. Duplicate entries were removed unless
they were identiﬁed as independent cleavage events
either by experiment or sequence variation in the spacer.
Several classiﬁers including SVMs, decision trees and
Naı¨ve Bayes were tested in 10-fold cross-validation
analyses using WEKA v3.5.7 (13). Naı¨ve Bayes performed
as well or better than the rest of the classiﬁers and was
used exclusively going forward in this study. The test set
was built from human genome build HG36 was parsed
into similar windows using spacers of 5 and 6 nt separating
the two zinc ﬁnger half-sites.
Validation of putative cleavage sites
Individual windows are scored 0 to 1 with windows of
lower scores representing sequences that are more likely
to be cleaved by the CCR5 ZFNs. K562 cells were treated
with catalytically active CCR5-224 ZFNs or a vector-only
control, genomic DNA was harvested, and deep
sequencing was used to analyze loci of interest as
described in Pattanayak et al. (8), with the exception
that sequencing was carried out for each paired-end
library with a 150-cycle MiSeq run (Illumina; Harvard
Biopolymers Facility, Boston, MA for CCR5 samples
and Dana Farber Cancer Institute for VEGFA samples).
Oligonucleotides used to amplify genomic loci of interest
are listed in Supplementary Table S10.
Data processing to identify putative mutagenic
NHEJ events
Individual reads were mapped using primer sequences to
the individual amplicons and aligned using the
Needleman–Wunsch algorithm with afﬁne gap penalties
(14). Alignments with <40 bp (minimum combined
length of primer) to the reference were excluded, and
targets with <1500 reads in either the treated or untreated
samples were excluded. Individual alignments were
combined to generate a multiple sequence alignment.
Identical alignments were counted, condensed and
veriﬁed to map HG37.57 using BLAT (http://www.
kentinformatics.com/). Sequences that mapped preferen-
tially to an alternate target were excluded. Potential NHEJ
events required indels of at least 2 nt in length that
originated from within the spacer between the ZFN half-
sites.
RESULTS
We sought to improve the original strategy of Liu and
colleagues by addressing its inability to interrogate
cleavage site libraries in vitro to a depth sufﬁcient to
identify all possible off-target sites present in the human
genome. To do this, we added a machine-learning-based
step that uses cleavage site preferences from the in vitro
selection experiments to predict what sequences in the
human genome are most likely to be cleaved (Figure 1).
We used standard machine-learning techniques to con-
struct Naı¨ve Bayes classiﬁers that quantify how the nu-
cleotide identity at each position within a DNA site differs
between members of a partially degenerate library that
were cleaved efﬁciently in vitro and those that were not
(‘Materials and Methods’ section). The scores generated
by each classiﬁer range from 0 to 1, with lower scores
representing a higher probability that any given site will
be cleaved (‘Materials and Methods’ section).
We performed an initial test of our approach by de-
veloping a classiﬁer based on in vitro site selection data
previously obtained for ZFNs targeted to a site in the
human CCR5 gene. As shown in Supplementary
Table S1, application of this CCR5 ZFN classiﬁer to
the human genome resulted in the overwhelming
majority of potential target sites having a high classiﬁer
score: 11 421 321 184 of 11 421 337 066 potential sites
(99.999861%) received a score higher than 0.75. By
contrast, only 15 882 sites (0.000139% of all potential
sites) had a score lower than 0.75, and only 1123 sites
(0.00000983% of all potential sites) had a score below
0.5. Importantly, all 12 bona ﬁde off-target sites identiﬁed
previously by the in vitro cleavage site selection, and the
IDLV integration methods had scores below 0.75. In
addition, 11 of these 12 sites fall within the top 25%
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of sites with scores below 0.75 (Supplementary Table S2)
(8–10).
Having established classiﬁer score cutoffs that enable
identiﬁcation of all previously known off-target sites for
the CCR5-targeted ZFNs, we next prospectively tested
whether other sites with scores below 0.75 might
include additional bona ﬁde off-target sites. However, a
comprehensive analysis of all sites with scores below 0.75
would require deep sequencing of 15 882 different alleles,
an experiment that would be challenging and expensive
to perform, given the current cost of next-generation
sequencing. Therefore, we instead systematically
assessed a smaller sampling of sites by ﬁrst grouping
them based on their position in exonic or non-exonic
genomic sequence and then binning sites within each of
these groups according to their classiﬁer scores (i.e.—0.0
to 0.1, 0.1 to 0.2, etc.). To achieve high levels of nuclease
activity that would facilitate detection of lower frequency
off-target events, we used conditions described by Liu
and colleagues to overexpress CCR5-targeted ZFNs in
K562 cells (‘Materials and Methods’ section). We then
used deep sequencing to assess the top 13 scoring sites
(if available) within each bin for evidence of NHEJ-
mediated indel mutations in the genomic DNA of these
cells.
Analysis of 138 sites identiﬁed NHEJ-mediated indel
mutations not only at the intended CCR5 target site and
at a previously known off-target site in the CCR2 gene but
also at 21 new off-target sites (Table 1). As expected, the
percentage of bona ﬁde off-target sites found within each
classiﬁer score bin was inversely correlated with the mag-
nitude of the score (i.e.—a greater percentage of actual
off-target sites were identiﬁed in the lower score bins).
For example, 35% (16 of 46) of the screened targets
with scores in the ﬁrst tercile (lowest scores) showed sig-
niﬁcant evidence of NHEJ-mediated indel mutations
compared with 13% (6 of 46) and 2% (1 of 46) of sites
with scores in the second and third terciles, respectively
(Supplementary Table S3).
To test the generalizability of our classiﬁer-based
approach, we used it to predict off-target sites for
another pair of ZFNs targeted to the human VEGFA
locus (Supplementary Table S4). Previous work using
the in vitro cleavage site selection assay had identiﬁed a
large number of potential off-target sites for this ZFN pair
in human cells (Supplementary Table S5) (8). We used this
selection data to build a classiﬁer that we used to score
every possible site in the human genome (‘Materials and
Methods’ section). As we observed with the CCR5 classi-
ﬁer, only a small number (7242) of genomic sites had a
classiﬁer score below 0.75, and only 936 sites had a score
below 0.5. In addition, all 31 bona ﬁde off-target sites
identiﬁed previously with the in vitro selection data all
had scores below 0.6, with all but one of these sites
having scores below 0.5 (Supplementary Table S6). We
assessed 159 potential off-target sites (identiﬁed using
the same stratiﬁed sampling approach we used for the
CCR5 ZFNs) for evidence of off-target mutations from
genomic DNA of human cells in which the VEGFA-
targeted nucleases had been expressed. This systematic
stratiﬁed analysis identiﬁed 34 bona ﬁde off-target sites,
including eight that were previously identiﬁed by
Pattanayak et al. (8) and 26 that were novel (Table 2).
We note that that the majority of these novel off-target
sites had low classiﬁer scores, again demonstrating the pre-
dictive capability of our method (Table 2). Furthermore,
Figure 1. Schematic illustrating the original method by Pattanayak et al. (8) (blue arrows) and the enhanced approach that incorporates addition of
a classiﬁer-based step (green arrows).
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several of the sites we predicted to be off-target sites that
did not show a statistically signiﬁcant level of NHEJ mu-
tations in this study had been previously conﬁrmed as
off-targets when screened with a greater depth of
sequencing reads by Pattanayak et al. (8), suggesting
that a greater number of the predicted off-target sites
might show evidence of mutation with deeper sequence
sampling.
DISCUSSION
Our results show in silico abstraction of in vitro cleavage
data provides a strategy that more broadly identiﬁes all
potential off-target sites of ZFN activity in human cells
than previously described methods. Our classiﬁer-based
approach not only successfully re-identiﬁed all previously
known off-target sites for two different ZFNs but also
enabled the identiﬁcation of many additional novel off-
target sites, including some that differ from the target
sequence by as many as 8 (of 24) or 6 (of 18) bp for the
CCR5- or VEGFA-targeted ZFNs, respectively (Tables 3
and 4) (8–10). Because sequences harboring these numbers
of mismatches will occur frequently in the human genome,
identifying these off-targets would have been previously
intractable by simple mismatch counting approaches;
indeed, using such strategies would require screening
hundreds of thousands of potential sites (Supplementary
Tables S7 and S8).
Importantly, because we only assessed a small sampling
of the top scoring potential off-target sites in cells, we
believe that the full range of potential off-target sites for
the two ZFN pairs we examined is likely more expansive
than just those identiﬁed in this study. This expectation is
supported by another experimental screen (data not
shown) that identiﬁed six additional bona ﬁde off-
target sites for the CCR5-targeted ZFNs (Supplementary
Table S9 and Supplementary Discussion). Collectively,
these results clearly demonstrate that ZFN off-target
sites may occur at low rates much more widely on a
genome-wide scale than suggested by data from previously
described reports.
Although our data clearly demonstrate that sites with
low classiﬁer scores are highly enriched for bona ﬁde off-
target sites, our results also show that bona ﬁde off-
targets are present (albeit at a much lower frequency)
among loci with higher classiﬁer scores. This suggests
Table 1. Off-target sites for ZFNs targeted to CCR5 displaying signiﬁcant evidence of ZFN induced indels grouped by
classiﬁer probability score
Probability
score
Genomic targets with
ZFN indels over total
targets screened
Percentage of targets
with signiﬁcant evidence
of ZFN-induced indelsa
Number of targets in
human genome scored
in this range
Non-exons Exons
0–0.1 0 1/1 100% 1
0.1–0.2 1/4 1/1 40% 5
0.2–0.3 6/12 1/1 54% 60
0.3–0.4 2/12 1/6 17% 241
0.4–0.5 4/12 1/13 20% 816
0.5–0.6 2/12 2/11 17% 2155
0.6–0.7 0/13 0/13 0% 5947
0.7–0.75 0/13 1/13 4% 6657
aSigniﬁcant evidence of ZFN-induced indels as compared with background (controls receiving plasmid with no zinc ﬁngers)
was determined using a Fishers exact test and a P-value of 0.05.
Table 2. Off-target sites for ZFNs targeted to VEGFA displaying signiﬁcant evidence of ZFN induce NHEJ grouped by
classiﬁer probability score
Probability score Genomic targets with
ZFN indels over total
targets screened
Percentage of targets
with signiﬁcant evidence
of ZFN-induced indelsa
Number of targets in
human genome scored
in this range
Non-exons Exons
0–0.1 3/4 N/A 75% 4
0.1–0.2 6/12 2/2 57% 31
0.2–0.3 5/13 3/6 42% 96
0.3–0.4 4/12 0/13 16% 246
0.4–0.5 2/12 1/12 13% 559
0.5–0.6 2/13 0/13 8% 1187
0.6–0.7 2/12 2/10 9% 2295
0.7–0.75 0/12 3/12 13% 2824
aSigniﬁcant evidence of ZFN-induced indels as compared with background (controls receiving plasmid with no zinc ﬁngers)
was determined using a Fishers exact test and a P-value of 0.05.
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that comprehensive identiﬁcation of off-target sites will
require interrogation of a large number of loci by deep
sequencing. We expect that decreases in the price per
base and increases in the number of bases that can be
sequenced should increase the number of potential sites
with low classiﬁer scores that can be examined, thereby
enabling the identiﬁcation of a greater number of bona
ﬁde off-target sites. However, until such reductions
in sequencing costs become reality, an alternative
approach might be to look at off-targets with the best
scores or to pre-screen off-targets bioinformatically for
sites that fall in regions of high priority such as
promoters, exons and non-coding RNAs.
We note that the number of off-target sites identiﬁed
by our approach may be larger or smaller depending on
the cell type examined as well as the level and duration
of ZFN expression. Not all of the sites with low classiﬁer
scores we examined showed evidence of mutagenesis.
Potential reasons for this might include DNA methyla-
tion of the target site or chromatin status of the gene.
These parameters will be cell-type speciﬁc and would not
be accounted for by in vitro selections or in silico classi-
ﬁers. As large-scale efforts such as ENCODE and the
NIH Roadmap Epigenomics Mapping Project deﬁne
these variables in multiple different cell types, it may
be possible to use such information to prioritize sites
with low classiﬁer scores and thereby to increase the
yield of bona ﬁde off-target sites identiﬁed by deep
sequencing. In addition, we expressed ZFNs from a
strong constitutive CMV promoter using transiently
transfected plasmids and harvested genomic DNA from
cells 5 days post-transfection. Lower levels and shorter
durations of ZFN expression might be expected to
induce fewer off-target mutations, whereas higher levels
and longer durations might induce an even greater
number of such mutations.
Table 3. In vivo validated off-targets for ZFNs targeted to CCR5
Target sequence Score Sequence
identity to
on-target
Observed
indel rate
Validating study Gene Intron/Exon
GTCATCCTCATCCTGATAAACTGCAAAAG 0.028 24 36.0/40.0% Perez/Gabriel CCR5 Exon
43.5%/47.8% Pattanayak/Sander
GTCGTCCTCATCTTAATAAACTGCAAAAA 0.118 22 5.4%/5.8% Perez/Gabriel CCR2 Exon
10.0%/12.9% Pattanayak/Sander
TGCTTCCTCACCCCAGGTAAACTGGAACAG 0.133 18 0.25% Sander
CTCTCCCTCATCTCAGAGCAACTGTAAAAG 0.204 19 0.39% Sander
GCCAGCCTCAGCTTCTTCAACTGGAAAAG 0.209 19 0.07% Sander
CTCTTACTCTACATGTTAAACTGAAAAAG 0.215 18 0.06% Sander MAP3K7 Intron
CTGGGGCTCAGCACACTCAACTGTAAAAG 0.217 16 0.11% Sander DNER Intron
GCAGTCCTTATCCCAAGTGAACTGAAAAAG 0.219 18 0.05% Sander GRP Intron
CTCTTCCTCAGCATGATTAACTGTAATAG 0.228 18 2.40% Sander
GTCCTGCTCAGCAAAAGAAACTGAAAAAG 0.264 20 0.03% Pattanayak
GTAGTCCTCCTCCTGCTAAACTGCAATGG 0.270 19 2.13% Sander
GACTCCCTCTCCTGGATTAACTGTAAAAG 0.294 17 0.07% Sander SKAP2 Exona
GGTGCCCTCACCTTTTTAAACTGTTAAAG 0.306 17 0.60% Sander CAMTA1 Intron
GTTATCCTCAGCAAACTAAAACTGGAACAG 0.307 20 0.12%/0.082% Pattanayak/Sander WBSCR17 Intron
GGCCTCCTCATCTCTTTAAACTGGAAATG 0.322 20 3.80% Gabriel
AAAGTACTCATCCTTTAAGACTGAAAAAG 0.322 17 2.06% Sander EREG Intron
ACATTGCTCATCACAAAGTAACTGTAAAAG 0.342 17 0.81% Sander
GTCTTCCTGATGCTACCAAACTGGAAAAG 0.348 20 0.02% Pattanayak
TGGTTGCTCATCTCCAAGAAACTGGAAAGG 0.357 17 0.80% Sander
CCCCCCCTCATCCCAATTAACTGTAAAAT 0.364 17 0.11% Sander VANGL1 Exon
ACACACCTCTTCCTCATAAACTGGAAGAG 0.400 16 4.59% Sander
CCCATGCTCTGCCCAGTCAACTGGGAAAG 0.400 16 0.03% Sander
TGTGTCCTCTGCATCAGTAAACTGAAACAG 0.401 16 2.50% Sander DTD1 Intron
GTGTTGCTTCTCCCCATCAACAGGAAAAG 0.401 16 0.22% Sander
GGAGAATGCAGCTTCATAAACTGCAAAAG 0.401 16 0.03% Sander FBLIM1 Intron
TGAGACCTCATCTCTTAAAACTGTAATAG 0.405 17 2.40% Gabriel KDM2A Intron
GTCCTCCTCATTCACACAAACTGGAAGGG 0.408 19 0.87% Sander IQSEC1 Intron
AGAGGCCTCCTCTCTTTAAACTGTAACAG 0.421 16 0.10% Gabriel ZCCHC14 Intron
GGACTCCCTCTCCTGGATTAACTGTAAAAG 0.428 16 0.05% Sander SKAP2 Exona
TTGGTCCTCATTATAAATAAACTGAAAGGG 0.500 17 0.02% Sander
ATGGACCTCAGCAAAGTAAACTGGAAAAC 0.501 17 0.02% Sander
TATTTCCCCATCTCAATAAACTGCAATAG 0.505 18 0.07% Sander RAB3IP Exon
GTTCCCCTCAGCAATGTAAACTGGGAAAC 0.508 17 0.27% Sander DOPEY1 Exon
GTTTTCCTCATCAAAGCAAACTGCAAAAT 0.523 21 0.07% Pattanayak
GTCATCTTCATCAGCATAAACTGTAAAGT 0.542 20 0.33% Pattanayak TACR3 Intron
ATGTTCCTCATCTCCCGAAACTGCAAATG 0.593 20 0.07% Pattanayak KCNB2 Intron
GTCAACCTCAACACCTACAGACTGCAAAAG 0.603 21 0.06% Pattanayak
GTCATCCTCATCGCCATCAACCGACATGG 0.701 18 0.02% Sander MY07B Exon
GTCATCTTCATCAAAAGGAACTGCAAAAC 0.710 21 0.04% Pattanayak
aOverlaps with alternate SKAP site.
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More broadly, the combined strategy of using
in vitro cleavage site selection data together with
machine-learning-based classiﬁers might also be extended
to speciﬁcity information from other sources (e.g.–SELEX
or bacterial selection) and to deﬁne the speciﬁcities of
nucleases built on other platforms (e.g.—TALENs or
CRISPR-Cas RNA-guided nucleases). The use of
machine learning to improve the predictive power of
data derived from in vitro selection experiments could be
particularly useful for ZFNs composed of greater numbers
Table 4. In vivo validated off-targets for ZFNs targeted to VEGFA
Target sequence Score Sequence
identity to
on-target
Observed
indel rate
Validating study Gene Intron/Exon
AGCAGCGTCTTCGAGAGTGAGGA 0.059 18 14.48%/17.66% Pattanayak/Sander VEGF-A Exon
AGCATCGTCTGAAGTGAGTGAGGC 0.076 16 0.66%/1.45% Pattanayak/Sander
AGCAAAGTCTGTACTGAGTGAGGG 0.088 15 1.32% Pattanayak OPN5 Intron
AGCAACGTCATATTCAGTGAGGA 0.095 16 0.05%/0.19% Pattanayak/Sander
AGCAATGTCAAAAAGAGTGAGGC 0.115 15 0.15%/0.24% Pattanayak/Sander SIK3 Intron
AGCAGCGTCCTTCCTCAGTGAGAC 0.132 15 0.05% Sander
AGCACCGTCCCCCTCAGTGAGGC 0.136 15 0.28% Pattanayak PDE9A Intron
AGCAGCGTATCACATGAGTGAGGG 0.143 16 0.44%/0.99% Pattanayak/Sander
AGCAGCGTCTCCCTTGAGTGATGG 0.145 16 0.04% Pattanayak PTK2B Intron
AGCAACTTCATCTTGAGTGAGGG 0.145 15 0.03% Sander
AGCACGGTCATGATGAGTGAGGC 0.148 15 0.04%/0.18% Pattanayak/Sander PLXNA4 Exon
AGCAGGGTCAGGGCTGAGTGAGGC 0.152 16 0.26%/1.00% Pattanayak/Sander
AGCAGCGTCGTGTGGTGTGAGGT 0.155 16 0.40% Sander AK8 Intron
AGCATCGTCTTTCTGTGTGAGGC 0.161 15 0.27% Sander CTXN3 Exon
AGCAGAGTCAGACTTGAGTGAGGT 0.163 16 0.10% Pattanayak LOC550643 Intron
AGCAACGTCCATAGTGTGTGAGAA 0.181 15 0.64% Pattanayak GBF1 Intron
GGCAACGTCAACTCAGAGTGAGAA 0.202 15 0.04% Sander
AGCAGGGTCACACTAAAGTGAGGC 0.209 15 0.34% Sander
AGCAGCGTCTAGGGGGAGGGAGGG 0.209 16 0.56%/0.10% Pattanayak/Sander HAUS5 Exon-Intron
AGCAGCGGCCCGCAGAGGGAGGC 0.213 15 2.23% Sander
AGCAGTGTCAGCCATGAGGGAGGG 0.216 15 1.81% Sander BC04086 Intron
AGCAGCTTCTCCTGGGAGTGAGGG 0.224 16 0.32% Pattanayak
AGCAAAGTCCTTGGTAAGTGAGGG 0.225 14 0.79% Sander ERMP1 Exon
AGCAGAGTCTCTGAGAGTGAGGC 0.236 16 0.09% Pattanayak HEATR8 Intron
AGCATTGTCTCATGTGAGTGAGGT 0.258 15 0.60% Pattanayak
AGCACGGTCAGTCTTCAGTGAGGG 0.267 14 0.96% Sander EGLN3 Exon
AGCAGCGACGCCTGGGAGTGAGGT 0.268 16 1.11% Pattanayak
AGCAGCGGCGGCTGCAGTGAGGC 0.276 15 0.30% Pattanayak MTX2 Exon
AGCAGCGGCAGCGAGAGTGATGT 0.285 15 0.06% Sander KIF3C Exon
AGCATTGTCTCCTGGAGTGAGGG 0.294 15 0.05% Pattanayak
AGCACAGTCAATCTTCAGTGAGGG 0.301 14 0.05% Sander DERA Intron
AGCTCCGGCAGACATGAGTGAGGG 0.302 14 0.07% Sander CDKL3 Intron
AGCATGGTCCCAAGGAGTGAGGG 0.304 15 0.16%/0.21% Pattanayak/Sander HRASLS Intron
GGCAGAGTCAGGGCTGAGTGAGGC 0.305 15 0.03% Sander CELF4 Intron
AGCATCGTCTTCTGTGAGTGAGTA 0.314 16 0.06% Pattanayak MICAL3 Intron
AGCACCGTGGCTTCGAGTGAGGC 0.339 15 0.03% Pattanayak
AGAAACGTCGTGGAGGAGTGAGGG 0.352 15 0.04% Pattanayak
AGCAGTGTCAGGCTGGTGTGAGGA 0.361 16 2.10% Pattanayak
AGCAGTGTCAGGCTGGTGTGAGGA 0.361 16 2.80% Pattanayak
AGCAGCGTGCAGTGACAGTGAGGC 0.400 15 0.04% Sander SYT9 Intron
AGCAAGGTCCATCCAGAGAGAGGC 0.402 14 0.22% Sander EVL Intron
AGCAGCGTCTGAAAGAGTGAAAA 0.413 16 0.07% Pattanayak
TGCAGCGGCGTAGGGGAGTGAGGA 0.426 16 0.07% Pattanayak SARDH Intron
AGCAGAGTCCAGTGGGTGTGAGGC 0.432 15 0.05% Sander SLC22A23 Exon
AGCATAGTCTAGGCCGAGTGAGGC 0.435 15 0.06% Pattanayak
AGCAGTGTCAGGCTGGTGTGAGGA 0.461 16 0.34% Pattanayak
AGCAGTGTCAGGCTGGTGTGAGGA 0.461 16 0.15% Pattanayak
AGCAGTGTCAGGCTGGTGTGAGGA 0.461 16 0.11% Pattanayak
AGCAAGGTCCACCAGGTGGGAGGG 0.500 13 0.01% Sander CHST11 Intron
AGTAGTGTCTCAGAAGAGGGAGGG 0.501 14 0.61% Sander CNBD1 Intron
AGCAGTGTCCTAAGGGGGTGAGGA 0.570 16 0.13% Pattanayak SBF2 Intron
AGTAAGGTCACTCATAAGTAAGGT 0.600 12 5.10% Sander
TGCAGCGGCGGCGGGAGGGAGGG 0.600 14 0.01% Sander
TGCACCGTCAAGAGTCAGTGAGAA 0.605 14 0.04% Sander BEND4 Exon
AGCCAGGTCACAGCTGAGAGAGGC 0.613 13 0.02% Sander ANGPLT7 Exon
AGCAGCGGCCGCCTGAGGGGAGC 0.701 13 3.11% Sander CHAF1A Exon
AGCAACAGCCCTGGGGGGTGAGGT 0.704 13 0.01% Sander FBLN2 Exon
AGCAACTGCGAGCTGGGTGAGGC 0.705 13 0.08% Sander PRDZ Exon
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of ﬁngers in each monomer and for TALENs. These nu-
cleases target longer sites, making it challenging to ad-
equately sample all potential off-targets even in an
in vitro system. Continuing to better deﬁne off-target
effects of targeted nucleases will provide important
information to guide reﬁnement of the genome-wide
speciﬁcities of these reagents. These improvements will
be critically important, as these targeted nucleases are
more widely applied for both research and therapeutic
approaches.
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